Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Jul;33(4):223–230. doi: 10.1007/BF01744941

Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue

Efraim Lavie 1,✉, David L Hirschberg 2, George Schreiber 2, K Thor 3, Lucas Hill 4, Ingegerd Hellstrom 2, Karl-Erik Hellstrom 2
PMCID: PMC11038951  PMID: 2059966

Abstract

Measurements in cancer patients showed that the pH of tumors averages 0.8 unit lower than that of the surrounding normal tissues, confirming published work. Based on this, the anti-carcinoma monoclonal antibody (mAb) L6 was used to prepare immunoconjugates with daunomycin (DM), the drug being released at the acidic pH of the tumor. A direct linking of the aconitic derivative of DM (AcoDM) to mAb L6 led to conjugates that either had a low drug/antibody ratio (<5:1) or precipitated in vitro. In order to increase the drug load and avoid precipitation, several biopolymers were tested as spacers between the drug and the L6. To attach the polymer derivative to the mAb, the former was maleimidized and the mAb was thiolated. The AcoM/mAb ratio obtained was 20, and the mAb retained its highly specific binding to tumor cells. At pH 6 the AcoDM-L6 conjugate was toxic to cultured C-3347 carcinoma cells with an inhibitory concentration (IC50) of 5 µg/ml. The conjugate was less effective than the free DM with an IC50 of 0.2 µg/ml. The L6 alone was not toxic. At a tumor pH of 6.5, 15% of the AcoDM was released. The amount of released drug reached a maximum 24–48 h after exposure to the acidic medium.

In vivo localization studies demonstrated a similar tumor uptake of the conjugate and mAb L6 with 18% of the injected dose/g tumor and a maximum uptake in tumor 48 h after injection. Our data indicate that it is possible to construct conjugates based on a pH-sensitive linker that can be targeted successfully to a tumor with release of a portion of the drug at the tumor site, but testing is needed to establish whether such release has anti-tumor activity in vivo and offers an advantage over treatment with unconjugated drug.

Key words: L6-daunomycin conjugates, Monoclonal antibody, Drug release

References

  • 1.Arnold IJ., Jr Polylysine-drug conjugates. Methods Enzymol. 1985;112:270–285. doi: 10.1016/s0076-6879(85)12023-9. [DOI] [PubMed] [Google Scholar]
  • 2.Arnold IJ, Jr, Dagan A, Gutheil JC, Kaplan NO. Antineoplastic activity of polylysine with some ascites tumor cells. Proc Natl Acad Sci, USA. 1979;76:3246–3250. doi: 10.1073/pnas.76.7.3246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ashby BS, Cantab MB. pH studies in human malignant tumors. Lancet. 1966;2:312–315. doi: 10.1016/s0140-6736(66)92598-0. [DOI] [PubMed] [Google Scholar]
  • 4.Beaumier PL, Neuzil D, Yang H-M, Noll EA, Krohn K, Hellstrom I, Hellstrom KE, Nelp W. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J Nucl Med. 1986;27:824–828. [PubMed] [Google Scholar]
  • 5.Bradford MD. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–284. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  • 6.Bumol TF, Laguzza BC, Dehardt SV. KS1/4-4 deacetyl vinblastine-3-carbohydrazide (KS1/4 DAVLB-Hydrazine): preclincal studies on monoclonal antibody drug conjugate for site directed therapy of human adenocarcinoma. Annu Meet Am Assoc Cancer Res. 1976;28:393. [Google Scholar]
  • 7.Croce AC, Prosperi E, Supino R, Bottiroli G. Anthracyclineinduced inhibition of membrane permeability function dependent on metabolic energy. Br J Cancer. 1986;54:943–950. doi: 10.1038/bjc.1986.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Deen WM, Satvat B (1981) Determinations of the glumerular filtration of proteins. Am J Physiol F162–F170 [DOI] [PubMed]
  • 9.Diener E, Diner UE, Sinha A, Xie S, Vergidis R. Specific immunosuppression by immunotoxinl containing daunomycin. Science. 1986;231:148–150. doi: 10.1126/science.3484557. [DOI] [PubMed] [Google Scholar]
  • 10.Dillman RA, Shawles DL, Johnson DE, Myer DL, Koziol JA, Frincke JM. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorobucin. Cancer Res. 1986;46:4886–4891. [PubMed] [Google Scholar]
  • 11.Ellman GL. Tissue sulfhydryl groups. Arch Biochem, Biophys. 1959;82:70–77. doi: 10.1016/0003-9861(59)90090-6. [DOI] [PubMed] [Google Scholar]
  • 12.FitzGerald DJ, Willingham MC, Pastan I. Antitumor effects of an immunotoxin made withPseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc Natl Acad Sci USA. 1986;83:6627–6630. doi: 10.1073/pnas.83.17.6627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Garrigues HJ, Tilgen W, Hellstrom I, Franke W, Hellstrom KE. Detection of human melanoma-associated antigen, P97, in histological sections of primary human melanoma. Int J Cancer. 1982;29:511–515. doi: 10.1002/ijc.2910290505. [DOI] [PubMed] [Google Scholar]
  • 14.Gerweck LE. Hyperthermia in cancer therapy: the biological basis and unresolved questions. Cancer Res. 1985;45:3408–3414. [PubMed] [Google Scholar]
  • 15.Grassetti DR, Murray JF., Jr Determination of sulfhydryl groups with 2—2″- or 4—4″ dithiodipyridine. Arch Biochem Biophys. 1960;119:41–49. doi: 10.1016/0003-9861(67)90426-2. [DOI] [PubMed] [Google Scholar]
  • 16.Hellstrom I, Beaumier PL, Hellstom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA. 1986;83:7059–7063. doi: 10.1073/pnas.83.18.7059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V., Hellstrom KE. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer. 1986;46:3917–3923. [PubMed] [Google Scholar]
  • 18.Ishikawa E, Imagawa M, Hashida S, Yoshitaka S, Hamaguci Y, Ueno T. Enzyme-labeling of antibodies and their fragments for enzyme-immunoassay and immunohistochemical staining. J Immunoassy. 1983;4:209–327. doi: 10.1080/15321818308057011. [DOI] [PubMed] [Google Scholar]
  • 19.Jahde E, Rajewsky MF. Tumor-selective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in the normal and malignant rat tissues. Cancer. 1982;42:1505–1512. [PubMed] [Google Scholar]
  • 20.Lavie E, Beaumier PL, Brodzinski L, Hellstrom KE, Hellstrom I. Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice. Radiother Oncol. 1989;15:295–305. doi: 10.1016/0167-8140(89)90098-4. [DOI] [PubMed] [Google Scholar]
  • 21.Liu F-T, Zinnecker M, Hamaoka T, Katz DH. New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates. Biochemistry. 1979;18:690–697. doi: 10.1021/bi00571a022. [DOI] [PubMed] [Google Scholar]
  • 22.Paschen W, Djuricic B, Miles G, Schmidt-Kastner F, Linn F. Lactate and pH in brain: association and dissociation in different pathophysiological states. J Neurochem. 1987;48:154–159. doi: 10.1111/j.1471-4159.1987.tb13140.x. [DOI] [PubMed] [Google Scholar]
  • 23.Rotin D, Wan P, Grinstein S, Tannock I. Cytotoxicity of compounds that interfere with the regulation of intracellular pH: a potential new class of anticancer drugs. Cancer Res. 1987;47:1497–1504. [PubMed] [Google Scholar]
  • 24.Rowland GF, Axton CA, Baldwin RW, Brown JP, Corvalan JRV, Ebelton MJ, Gore Va, Hellstrom I, Hellstrom KE, Jacobs E, Marsden CH, Pimm MV, Simonds RG, Smith W. Antitumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother. 1985;19:1–7. doi: 10.1007/BF00199304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ryser HJ-P, Shen W-C. Conjugation of poly-l-lysine increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA. 1978;75:3867–3870. doi: 10.1073/pnas.75.8.3867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Senter PD, Saulinier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE. Antitumor effects of antibody alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA. 1988;85:4842–4846. doi: 10.1073/pnas.85.13.4842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shen W-C, Ryser HJ-P. Conjugation of poly-l-lysine to albumin and horseradish perozidase: a novel method of enhancing the cellular uptake of proteins. Proc Natl Acad Sci USA. 1978;75:1872–1876. doi: 10.1073/pnas.75.4.1872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Shen W-C, Ryser HJ-P. cis-Aconityl spacer between daunomycin and macromolecular carrier: a model of pH sensitive linkage releasing drug from lysosomotropic conjugate. Biochem Biphys Res Commun. 1981;102:1048–1054. doi: 10.1016/0006-291x(81)91644-2. [DOI] [PubMed] [Google Scholar]
  • 29.Shen W-C, Yang D, Ryser HJ-P. Colorimetric determination of microgram quantities of polylysine by trypan blue precipitation. Anal Biochem. 1984;142:521–524. doi: 10.1016/0003-2697(84)90500-1. [DOI] [PubMed] [Google Scholar]
  • 30.Thistlethawaite AJ, Leeper DB, Moylan DJ, Nerlinger RE. pH distribution in human tumors. Int J Radiat Oncol Biol Phys. 1985;11:1647–1652. doi: 10.1016/0360-3016(85)90217-2. [DOI] [PubMed] [Google Scholar]
  • 31.Thorpe PE, Mason DW, Brown ANF, Simmonds SJ, WC, Cumber AJ, Forrester JA. Selective killing of mallignant cells in leukemic rat bone marrow using an antibody-ricin conjugate. Nature. 1982;297:594. doi: 10.1038/297594a0. [DOI] [PubMed] [Google Scholar]
  • 32.Trouet A, Masquelier M, Baurain R, Deprez-De Campeneere DA. Covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for lysosonotropic drug-carrier conjugate: In vitro and in vivo studies. Proc Natl Acad Sci USA. 1982;79:626–629. doi: 10.1073/pnas.79.2.626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tsukada I, Bichof WK, Hibi N, Hirai H, Hurwitz E, Sela M. Effect of conjugates of daunomycin and antibodies to rat alphafetoprotein-producing tumor cells. Proc Natl Acad Sci USA. 1982;79:621–626. doi: 10.1073/pnas.79.2.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yeh M-Y, Hellstrom I, Hellstrom KE. Clonal variation in expression of human melanoma antigen defined by monoclonal antibody. J Immunol. 1981;126:1312–1317. [PubMed] [Google Scholar]
  • 35.Zunino F, Savi G, Giuliani F, Gambetta RO, Supino R, Tinelli S, Fezzoni G. Comparison antitumor effects of daunorubicin covalently linked to poly-l-amino acids carriers. Eur J Cancer Clin Oncol. 1984;20:421–425. doi: 10.1016/0277-5379(84)90091-9. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES